about
The pro-apoptotic kinase Mst1 and its caspase cleavage products are direct inhibitors of Akt1The PI3K pathway as drug target in human cancerAKT/PKB signaling: navigating downstreamMechanistic Insights into Molecular Targeting and Combined Modality Therapy for Aggressive, Localized Prostate CancerThe atypical PKCs in inflammation: NF-κB and beyondA comprehensive panel of three-dimensional models for studies of prostate cancer growth, invasion and drug responsesSIRT3 inhibits prostate cancer by destabilizing oncoprotein c-MYC through regulation of the PI3K/Akt pathway.MYC cooperates with AKT in prostate tumorigenesis and alters sensitivity to mTOR inhibitorsTargeted therapy for advanced prostate cancer: inhibition of the PI3K/Akt/mTOR pathwayAntitumor activity and mechanism of action of the cyclopenta[b]benzofuran, silvestrolDiscovery of novel AKT inhibitors with enhanced anti-tumor effects in combination with the MEK inhibitorConcurrent HDAC and mTORC1 inhibition attenuate androgen receptor and hypoxia signaling associated with alterations in microRNA expressionThe lncRNA DRAIC/PCAT29 Locus Constitutes a Tumor-Suppressive Nexus.The current state of preclinical prostate cancer animal models.Akt-dependent regulation of NF-{kappa}B is controlled by mTOR and Raptor in association with IKK.Monoclonal antibody targeting of N-cadherin inhibits prostate cancer growth, metastasis and castration resistanceVEGF/neuropilin-2 regulation of Bmi-1 and consequent repression of IGF-IR define a novel mechanism of aggressive prostate cancerMP470, a novel receptor tyrosine kinase inhibitor, in combination with Erlotinib inhibits the HER family/PI3K/Akt pathway and tumor growth in prostate cancerAccumulating progenitor cells in the luminal epithelial cell layer are candidate tumor initiating cells in a Pten knockout mouse prostate cancer modelPromoter- and cell-specific epigenetic regulation of CD44, Cyclin D2, GLIPR1 and PTEN by methyl-CpG binding proteins and histone modifications.Fish oil targets PTEN to regulate NFkappaB for downregulation of anti-apoptotic genes in breast tumor growth.Loss of PTEN expression in breast cancer: association with clinicopathological characteristics and prognosis.Comprehensive evaluation of the role of EZH2 in the growth, invasion, and aggression of a panel of prostate cancer cell linesCXCR6 induces prostate cancer progression by the AKT/mammalian target of rapamycin signaling pathway.Beta1 integrins mediate cell proliferation in three-dimensional cultures by regulating expression of the sonic hedgehog effector protein, GLI1.Rapamycin selectively reduces the association of transcripts containing complex 5' UTRs with ribosomes in C4-2B prostate cancer cells.Average rank-based score to measure deregulation of molecular pathway gene setsTargeting tumor metabolism with 2-deoxyglucose in patients with castrate-resistant prostate cancer and advanced malignancies.Caffeic acid phenethyl ester causes p21 induction, Akt signaling reduction, and growth inhibition in PC-3 human prostate cancer cells.RAS Interaction with PI3K: More Than Just Another Effector PathwaymiRNA-34b inhibits prostate cancer through demethylation, active chromatin modifications, and AKT pathways.Reduction of Pten dose leads to neoplastic development in multiple organs of Pten (shRNA) miceTargeting proapoptotic protein BAD inhibits survival and self-renewal of cancer stem cellsConcomitant loss of EAF2/U19 and Pten synergistically promotes prostate carcinogenesis in the mouse model.Phospho-MED1-enhanced UBE2C locus looping drives castration-resistant prostate cancer growth.Castration-resistant prostate cancer: new science and therapeutic prospects.AKT signalling in the failing heartAKT inhibitors promote cell death in cervical cancer through disruption of mTOR signaling and glucose uptake.Identification of PHLPP1 as a tumor suppressor reveals the role of feedback activation in PTEN-mutant prostate cancer progression.MED1 mediates androgen receptor splice variant induced gene expression in the absence of ligand
P2860
Q24297392-8E7D6399-78E3-4E6E-8C86-8E5BC56EA72BQ24632283-A37C7936-40B2-432F-A0EA-CF06C23C858EQ24657857-0EF12F3F-E52A-4232-8299-EA109E0D8B53Q26766638-41E9C735-04DB-4BAA-BE74-24BC98948E0FQ26829823-1C48227D-B4DC-4C76-86EF-F8F50F8BDDEAQ27329871-44CBF598-DA98-4956-92BF-8AC73A4C7915Q27341759-132D075F-5F55-4BB8-A1E6-2741DFAFBD65Q27350187-475272EE-A2D4-42D1-AAB2-AFED47104ECBQ28382812-07765561-4204-4CAF-86C7-110A0C5A551EQ28475419-E8584ACC-76DC-4407-9B4E-DCA17F648972Q28540161-B3CFDA92-E5E5-4CA2-8545-EE4395A879A6Q28743074-7017135C-2F66-44A3-8027-59D7CAF79351Q30300669-94901C50-2A7D-4ED9-A780-2C349CC7EE01Q30418797-744A7771-5290-4836-BCD5-0A37CD03985CQ30440717-6831B4F7-B92B-4477-B1C4-EF3C1DFEDB3BQ30500080-877F2F3F-6599-487F-89E6-D5108DB41CF3Q30595149-9C73950A-BF9D-461F-AE81-0FEDCE07C118Q33443571-4A70DADE-CEE0-46AA-A68D-8206CBD8FB40Q33450599-F3CC8474-D564-4E72-B7F2-18163CF425CCQ33610854-E72CF997-1B24-4A0C-B8E4-68D1367B7776Q33761221-35DFAA20-8412-4121-9FFC-CA529BF517F3Q33762003-662A3119-1CF8-42E3-B55F-5EAC8AC73E93Q33766326-0EFF4BFF-85B7-4E67-B26A-3B79297FC39FQ33909085-68B298F0-B232-4B1D-80BB-BDAD978ECB67Q33914011-C410CF94-DCB0-460A-9EE0-3C246C501413Q34033097-54FB396F-8DC3-44DA-A031-08A769C59CEEQ34077968-F1BBCB0F-7D31-4A6B-9620-32382F8C868DQ34081705-649EBD4B-3079-47C4-A979-737ACD97B072Q34162761-2DA6AB9A-3AB6-4DC9-AD46-839A7DA0CDA5Q34202692-68A8B760-3744-4D39-80A1-0621685E3EC5Q34311399-2670EA90-EC46-4FDD-94EA-0A26D9EDD358Q34479331-1C30DA93-22AB-40EB-875C-238336307D54Q34486457-2ECF67F2-630C-4452-9411-32ED53264C8BQ34740903-6F773F45-4D83-4DC0-9046-7E8249632CB0Q35048908-3D9952A8-4993-4D6F-808D-811804F6AA31Q35076264-0A84AC29-9BB7-4EA8-81FA-601BE3D59ED4Q35128548-817DA630-68DE-4FDE-B1D6-E17C3ECE9B5BQ35140099-0383CCA9-E323-443F-9F55-CBFB0794F9ADQ35223274-1C46FAF2-9E61-437A-9495-85D99EAE48A5Q35238452-9B06BB41-064C-4BC5-A02A-468C80CA57E0
P2860
description
2005 nî lūn-bûn
@nan
2005年の論文
@ja
2005年学术文章
@wuu
2005年学术文章
@zh-cn
2005年学术文章
@zh-hans
2005年学术文章
@zh-my
2005年学术文章
@zh-sg
2005年學術文章
@yue
2005年學術文章
@zh
2005年學術文章
@zh-hant
name
Akt-regulated pathways in prostate cancer.
@ast
Akt-regulated pathways in prostate cancer.
@en
type
label
Akt-regulated pathways in prostate cancer.
@ast
Akt-regulated pathways in prostate cancer.
@en
prefLabel
Akt-regulated pathways in prostate cancer.
@ast
Akt-regulated pathways in prostate cancer.
@en
P2860
P356
P1433
P1476
Akt-regulated pathways in prostate cancer.
@en
P2093
Pradip K Majumder
William R Sellers
P2860
P2888
P304
P356
10.1038/SJ.ONC.1209096
P407
P577
2005-11-01T00:00:00Z